Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...
1don MSN
The Fukushima Daiichi nuclear power plant's radiation levels have significantly dropped since the cataclysmic meltdown 14 ...
Interesting Engineering on MSN1d
Fukushima disaster: 14 years into Japan’s battle to remove 880 tons of nuclear debrisFourteen years after the devastating earthquake and tsunami led to the Fukushima Daiichi nuclear accident, the site has made ...
On March 11, 2025, we remember the profound loss and resilience of the people of Japan following the Great East Japan ...
Fourteen years after the Fukushima Daiichi meltdown, radiation levels have decreased, but decommissioning efforts remain ...
Clinical Trials Arena on MSN9d
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trialDaiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
J.P. Morgan analyst Seiji Wakao maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on March 5 and set a price target ...
Nosis Biosciences Announces Research Collaboration and Option Agreement with Daiichi Sankyo to Develop Cell-Targeted RNA Medicines ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Japan’s top court has found two former company executives not guilty of negligence over the 2011 Fukushima Daiichi nuclear power plant disaster and the subsequent deaths of dozens of elderly residents ...
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback